Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study.
Lewis L, Sookrajh Y, van der Molen J, Khubone T, Sosibo P, Maraj M, van Heerden R, Little F, Kassanjee R, Garrett N, Dorward J. Lewis L, et al. Among authors: van heerden r. J Int AIDS Soc. 2023 Sep;26(9):e26164. doi: 10.1002/jia2.26164. J Int AIDS Soc. 2023. PMID: 37767825 Free PMC article.
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N. Dorward J, et al. Among authors: van heerden r. Lancet HIV. 2023 May;10(5):e284-e294. doi: 10.1016/S2352-3018(23)00047-4. Epub 2023 Mar 28. Lancet HIV. 2023. PMID: 37001536 Free PMC article.
Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J. Asare K, et al. Among authors: van heerden r. Lancet Glob Health. 2024 Feb;12(2):e282-e291. doi: 10.1016/S2214-109X(23)00516-8. Epub 2023 Dec 21. Lancet Glob Health. 2024. PMID: 38142692 Free PMC article.
Spread in climate policy scenarios unravelled.
Dekker MM, Hof AF, van den Berg M, Daioglou V, van Heerden R, van der Wijst KI, van Vuuren DP. Dekker MM, et al. Among authors: van heerden r. Nature. 2023 Dec;624(7991):309-316. doi: 10.1038/s41586-023-06738-6. Epub 2023 Dec 13. Nature. 2023. PMID: 38092909 Free PMC article.
Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study.
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J. Asare K, et al. Among authors: van heerden r. medRxiv [Preprint]. 2023 Jul 8:2023.07.07.23292347. doi: 10.1101/2023.07.07.23292347. medRxiv. 2023. PMID: 37461582 Free PMC article. Preprint.